230 related articles for article (PubMed ID: 31705375)
21. TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES.
Teixeira FV; Damião AOMC; Kotze PG
Arq Gastroenterol; 2018; 55(2):198-200. PubMed ID: 30043874
[TBL] [Abstract][Full Text] [Related]
22. Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data.
Varyani F; Argyriou K; Phillips F; Tsakiridou E; Moran GW
Drug Des Devel Ther; 2019; 13():4091-4105. PubMed ID: 31819376
[TBL] [Abstract][Full Text] [Related]
23. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.
Colombel JF; Osterman MT; Thorpe AJ; Salese L; Nduaka CI; Zhang H; Lawendy N; Friedman GS; Quirk D; Su C; Reinisch W
Clin Gastroenterol Hepatol; 2022 Jan; 20(1):116-125.e5. PubMed ID: 33039585
[TBL] [Abstract][Full Text] [Related]
24. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
Mukherjee A; Hazra A; Smith MK; Martin SW; Mould DR; Su C; Niezychowski W
Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257
[TBL] [Abstract][Full Text] [Related]
25. [Tofacitinib for the treatment of ulcerative colitis. Report of two cases].
Quera R; Flores L; Núñez P; Ibáñez P
Rev Med Chil; 2020 Jul; 148(7):1039-1043. PubMed ID: 33399691
[No Abstract] [Full Text] [Related]
26. Esophageal Ulcer in a Lung Cancer Patient. Crizotinib-induced Esophageal Injury.
Sawada T; Maeno K; Joh T
Gastroenterology; 2015 Aug; 149(2):e6-7. PubMed ID: 26123560
[No Abstract] [Full Text] [Related]
27. Tofacitinib in Acute Severe Ulcerative Colitis-A Real-World Tertiary Center Experience.
Honap S; Pavlidis P; Ray S; Sharma E; Anderson S; Sanderson JD; Mawdsley J; Samaan MA; Irving PM
Inflamm Bowel Dis; 2020 Oct; 26(11):e147-e149. PubMed ID: 32566937
[No Abstract] [Full Text] [Related]
28. Tofacitinib in ulcerative colitis.
Archer TP; Moran GW; Ghosh S
Immunotherapy; 2016 May; 8(5):495-502. PubMed ID: 27140405
[TBL] [Abstract][Full Text] [Related]
29. Experience with tofacitinib in patients with refractary ulcerative colitis.
López González J; Hernández Martínez Á; Lázaro Sáez M; Vega Sáenz JL
Gastroenterol Hepatol; 2021 Apr; 44(4):300-301. PubMed ID: 33051048
[No Abstract] [Full Text] [Related]
30. Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials.
Panés J; Vermeire S; Dubinsky MC; Loftus EV; Lawendy N; Wang W; Salese L; Su C; Modesto I; Guo X; Colombel JF
J Crohns Colitis; 2021 Nov; 15(11):1852-1863. PubMed ID: 33884415
[TBL] [Abstract][Full Text] [Related]
31. Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib.
Noell C; Arbeit R; Kanhoush R
Dermatol Online J; 2018 Jan; 24(1):. PubMed ID: 29469766
[TBL] [Abstract][Full Text] [Related]
32. Use of Tofacitinib for Ulcerative Colitis in a Liver Transplant Patient.
Meunier L; Clerc C; Meszaros M
J Crohns Colitis; 2021 Apr; 15(4):695. PubMed ID: 32072164
[No Abstract] [Full Text] [Related]
33. Pharmacology and safety of tofacitinib in ulcerative colitis.
López-Sanromán A; Esplugues JV; Domènech E
Gastroenterol Hepatol; 2021 Jan; 44(1):39-48. PubMed ID: 32829958
[TBL] [Abstract][Full Text] [Related]
34. Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis.
Sandborn WJ; Armuzzi A; Liguori G; Irving PM; Sharara AI; Mundayat R; Lawendy N; Woolcott JC; Danese S
Inflamm Bowel Dis; 2022 Sep; 28(9):1338-1347. PubMed ID: 34958359
[TBL] [Abstract][Full Text] [Related]
35. A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib.
Sato S; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Furuya M; Gunji N; Fujiwara T; Asano T; Onizawa M; Kobayashi H; Watanabe H; Ohira H; Migita K
Rheumatology (Oxford); 2020 Jul; 59(7):1773-1775. PubMed ID: 31776552
[No Abstract] [Full Text] [Related]
36. Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.
Chaparro M; Garre A; Mesonero F; Rodríguez C; Barreiro-de Acosta M; Martínez-Cadilla J; Arroyo MT; Manceñido N; Sierra-Ausín M; Vera-Mendoza I; Casanova MJ; Nos P; González-Muñoza C; Martínez T; Boscá-Watts M; Calafat M; Busquets D; Girona E; Llaó J; Martín-Arranz MD; Piqueras M; Ramos L; Surís G; Bermejo F; Carbajo AY; Casas-Deza D; Fernández-Clotet A; García MJ; Ginard D; Gutiérrez-Casbas A; Hernández L; Lucendo AJ; Márquez L; Merino-Ochoa O; Rancel FJ; Taxonera C; López Sanromán A; Rubio S; Domènech E; Gisbert JP
J Crohns Colitis; 2021 Jan; 15(1):35-42. PubMed ID: 32969471
[TBL] [Abstract][Full Text] [Related]
37. Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis.
Panés J; Su C; Bushmakin AG; Cappelleri JC; Healey P
J Crohns Colitis; 2016 Nov; 10(11):1310-1315. PubMed ID: 27194530
[TBL] [Abstract][Full Text] [Related]
38. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience.
Honap S; Chee D; Chapman TP; Patel M; Kent AJ; Ray S; Sharma E; Kennedy J; Cripps S; Walsh A; Goodhand JR; Ahmad T; Satsangi J; Irving PM; Kennedy NA;
J Crohns Colitis; 2020 Oct; 14(10):1385-1393. PubMed ID: 32280965
[TBL] [Abstract][Full Text] [Related]
39. Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis.
Danese S; D'Amico F; Bonovas S; Peyrin-Biroulet L
Inflamm Bowel Dis; 2018 Sep; 24(10):2106-2112. PubMed ID: 29697791
[TBL] [Abstract][Full Text] [Related]
40. Tofacitinib for the treatment of ulcerative colitis.
Fernández-Clotet A; Castro-Poceiro J; Panés J
Expert Rev Clin Immunol; 2018 Nov; 14(11):881-892. PubMed ID: 30285500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
